当前位置： SCI文献检索 > CANCER期刊下所有文献 > Physician interpretation of genomic test results and treatment selection.

Physician interpretation of genomic test results and treatment selection.

Abstract：

BACKGROUND:Genomic testing is increasingly performed in oncology, but concerns remain regarding the clinician's ability to interpret results. In the current study, the authors sought to determine the agreement between physicians and genomic annotators from the Precision Oncology Decision Support (PODS) team at The University of Texas MD Anderson Cancer Center in Houston regarding actionability and the clinical use of test results. METHODS:On a prospective protocol, patients underwent clinical genomic testing for hotspot mutations in 46 or 50 genes. Six months after sequencing, physicians received questionnaires for patients who demonstrated a variant in an actionable gene, investigating their perceptions regarding the actionability of alterations and clinical use of these findings. Genomic annotators independently classified these variants as actionable, potentially actionable, unknown, or not actionable. RESULTS:Physicians completed 250 of 288 questionnaires (87% response rate). Physicians considered 168 of 250 patients (67%) as having an actionable alteration; of these, 165 patients (98%) were considered to have an actionable alteration by the PODS team and 3 were of unknown significance. Physicians were aware of genotype-matched therapy available for 119 patients (71%) and 48 of these 119 patients (40%) received matched therapy. Approximately 46% of patients in whom physicians regarded alterations as not actionable (36 of 79 patients) were classified as having an actionable/potentially actionable mutation by the PODS team. However, many of these were only theoretically actionable due to limited trials and/or therapies (eg, KRAS). CONCLUSIONS:Physicians are aware of recurrent mutations in actionable genes on "hotspot" panels. As larger genomic panels are used, there may be a growing need for annotation of actionability. Decision support to increase awareness of genomically relevant trials and novel treatment options for recurrent mutations (eg, KRAS) also are needed. Cancer 2018;124:966-72. © 2017 American Cancer Society.

journal_name

Cancer

journal_title

Cancer

authors

Brusco LL,Wathoo C,Mills Shaw KR,Holla VR,Bailey AM,Johnson AM,Khotskaya YB,Litzenburger BC,Sanchez NS,Zeng J,Bernstam EV,Eng C,Kee BK,Amaria RN,Routbort MJ,Mills GB,Mendelsohn J,Meric-Bernstam F

doi

10.1002/cncr.31112

subject

Has Abstract

pub_date

2018-03-01 00:00:00

pages

966-972

issue

eissn

0008-543X

issn

1097-0142

journal_volume

124

pub_type

杂志文章

在线工具

Physician interpretation of genomic test results and treatment selection.